Evaluation of Comparative efficacy of Triphlala Grita eye drops along with Shatavari Ksheerapaka versus shatavari Grita eye drops and Shatavari Ksheerapaka systemically in the management of post-menopausal dry eye- A Randomised Control Trial

开始日期2023-07-05

申办/合作机构-

ChiCTR2300071953 / Recruiting临床1期

Evaluation of the efficacy and safety of Golden Eye Drops for the treatment of dry eye - a multicenter, randomized, double-blind, placebo-controlled post-market clinical trial.

开始日期2023-06-01

申办/合作机构

北京同仁医院管理有限公司

NCT05784519 / Not yet recruiting早期临床1期IIT

Clinical Study of Mesenchymal Stem Cell Eye Drops for Treating Dry Eye Disease

The goal of this non-randomized, prospective, open, one-arm clinical study is to learn about the clinical efficacy of stem cell eye drops in patients with dry eye disease (DED) who failed to respond to artificial tear sodium hyaluronate eye drops three times a day for two weeks.
The main question aims to answer are:
How effective are stem cell eye drops in patients with DED?
How safe are stem cell eye drops for patients with DED? Participants will be treated with mesenchymal stem cells (MSCs) eye drops, 5×10^5 /50μl in each eye, twice a day for two weeks and they will be followed up for three months after treatment.

开始日期2023-06-01

申办/合作机构

南京鼓楼医院

100 项与 MSCs eye drops(Nanjing Drum Tower Hospital) 相关的临床结果

登录后查看更多信息

100 项与 MSCs eye drops(Nanjing Drum Tower Hospital) 相关的转化医学

登录后查看更多信息

100 项与 MSCs eye drops(Nanjing Drum Tower Hospital) 相关的专利（医药）

登录后查看更多信息

646

项与 MSCs eye drops(Nanjing Drum Tower Hospital) 相关的文献（医药）

2024-11-01·American Journal of Ophthalmology

A Comprehensive Meta-Analysis on the Role of Analgesics and Anti-Inflammatories in Pan-Retinal Photocoagulation

Review

作者: Barbosa, Larissa I T ; Arruda, Mateus P ; Lima, Rian V ; Zinher, Mariana T ; Souza, Camila L ; Hira, Sara ; Valle, Giulia S Del ; Moreira, João L M L

PURPOSEPan-retinal photocoagulation (PRP) is the mainstay of treatment for proliferative diabetic retinopathy (PDR), reducing the risk of severe vision loss. Pain poses a potential obstacle to effective laser delivery and patient compliance. Therefore, implementing pain relief strategies can enhance both treatment efficacy and patient comfort.DESIGNA systematic review and meta-analysis.METHODSWe conducted a systematic review and meta-analysis according to PRISMA guidelines. The PubMed, Embase and Cochrane Central Register of Controlled Trials databases were searched for randomized controlled trials (RCTs) that enrolled patients undergoing PRP due to DR and compared analgesics or non-steroidal anti-inflammatory drugs (NSAID) to placebo. Pain was evaluated with the visual analogue scale. The version 2 of the Cochrane Collaboration's Risk of Bias in Randomized Controlled Trials tool and its version for crossover trials were used to assess the risk of bias. The Grading of Recommendations, Assessment, Development, and Evaluation tool was used to measure the certainty of evidence.RESULTSA total of 13 studies were included, comprising 1404 eyes from RCTs, nine of which were crossover. Patients who were administered analgesia reported a significantly lower pain sensitivity compared to those who received placebo (Standardized mean difference [SMD] -0.38; 95% confidence interval [CI] -0.58, -0.17; P < .01; I² = 69%). Subgroup analysis of systemic administration of analgesics/NSAIDs (metamizole, Entonox, acetaminophen, ibuprofen, caffeine, mefenamic acid, intramuscular ketorolac tromethamine, and potassium diclofenac) also showed a statistically significant reduction in pain when compared to placebo (SMD -0.28; 95% CI -0.50, -0.07; P < .01; I² = 43%). Exclusive eye drops administration (ketorolac tromethamine 0.5% and sodium diclofenac 0.1%) also showed a significant difference in pain sensitivity (SMD -0.46; 95% CI -0.88, -0.05; I² = 83%), however with a more significant heterogeneity.CONCLUSIONSThe results of this meta-analysis including over 1000 patients demonstrated that the use of analgesics significantly reduced pain sensitivity during PRP, and systemic analgesia is potentially better than topical administration when compared to placebo.

2024-11-01·Die Ophthalmologie

Videobeitrag

Article

作者: Prinz, Julia ; Cursiefen, Claus ; Schaub, Friederike ; Walter, Peter ; Fuest, Matthias ; Prokosch, Verena ; Bachmann, Björn

OBJECTIVE OF SURGERYThe aim of this surgical technique is the implantation of a glaucoma drainage device (GDD) in eyes with aphakic glaucoma following injector-assisted implantation of an artificial iris into the ciliary sulcus.INDICATIONSThis atraumatic tube insertion technique can be performed during GDD implantation after implantation of an artificial iris into the ciliary sulcus.SURGICAL TECHNIQUEFollowing injector-assisted implantation of an artificial iris into the ciliary sulcus of eyes, the iris can shift into the chamber angle. The GDD should be positioned in the quadrant in which the iridectomy is located. Otherwise, GDD implantation is not possible due to the resistance of the artificial iris. Alternatively, the artificial iris can be easily and non-traumatically rotated in the ciliary sulcus by flushing the anterior chamber with balanced salt solution (BSS) to move the iridectomy into the desired area and position the GDD tube in the anterior chamber. A surgical video, which is available online, shows the surgical technique in detail.FOLLOW-UPAfter GDD, dexamethasone eye drops should be applied 8 times daily for 1 week tapering down by 1 drop per week thereafter. Antibiotic eye drops, e.g., ofloxacin eye drops, are prescribed 4 times daily for 1 week and might be discontinued thereafter.EVIDENCETo date, this is the first description of a rotation of an artificial iris located in the ciliary sulcus by irrigation of the anterior chamber during GDD implantation.

2024-11-01·Journal Français d'Ophtalmologie

Pterygium recurrence following preoperative topical Mitomycin C and 5-Fluorouracil eyedrops

Article

作者: Rajagopal, J ; Das, G.K. ; Sharma, S ; Das, G K ; Sahu, P K ; Sharma, S. ; Rajagopal, J. ; Sahu, P.K.

INTRODUCTIONVarious adjuvant therapies have been used to prevent recurrence after pterygium excision. However, no single agent has been proven to be a gold standard for completely preventing recurrence with no associated complications.PURPOSEThis study aims to compare the recurrence rate following preoperative topical mitomycin C (MMC) and 5-fluorouracil (5-FU) eye drops in pterygium excision surgery.METHODSIn this interventional longitudinal comparative study, 90 patients with primary pterygium attending the Ophthalmology Clinic were enrolled and randomized into three equal groups of 30 each. Groups A, B, and C received preoperative 0.02% MMC eye drops, 1% 5-FU eyedrops, and placebo treatment respectively for one week before surgery followed by pterygium excision with conjunctival autograft and histopathological analysis. Patients were followed for 6months to identify recurrence.RESULTSAt the end of the 6months, the recurrence rate in the preoperative MMC group (6.7%) was less than the 5-FU (13.3%) and placebo (20%) groups. The histopathological findings were consistent with pterygium tissues. There were high grades of inflammation, degeneration, and vascularization in both the MMC and 5-FU groups in the specimens which recurred within a period of 6months. Five patients had a novel finding of smooth muscle choristoma tissue with bundles of smooth muscle cells and fat cells clustered among the conjunctival tissue.CONCLUSIONBased on our study results, we demonstrate that preoperative topical MMC and 5-FU eyedrops have efficacy in reducing recurrence in pterygium surgeries. The eyedrop route of administration has been proven to be an effective and easier alternative, enabling us to monitor for adverse effects of adjuvant drugs. Histopathological evaluation provides indices to predict features of future recurrence in pterygium specimens. This is the first study in which the efficacy of preoperative MMC and 5-FU is studied in eyedrop formulation along with histopathological correlation with recurrence.

100 项与 MSCs eye drops(Nanjing Drum Tower Hospital) 相关的药物交易

登录后查看更多信息